Food Certifiers Pay Up: FDA's 2026 Fee Adjustment
Published Date: 7/30/2025
Notice
Summary
Starting in fiscal year 2026, the FDA is updating the fees for groups that check food safety under the Food Safety Modernization Act. This affects accreditation and certification bodies who want to get or keep their official approval. The new fees help keep food safety checks strong and fair, with changes kicking in soon to keep everyone on track.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
FY2026 Annual Fee for Recognized Bodies
Starting in fiscal year (FY) 2026, the FDA sets the annual fee rate that applies to already recognized accreditation bodies and accredited certification bodies in the FSMA third-party certification program. If you run or manage an accredited body, you will be charged this annual fee to keep your recognition and participation in the program.
Fee for Direct FDA Accreditation Applicants
The FDA announces the fee rate for certification bodies that apply for direct FDA accreditation in fiscal year 2026. If your certification body is seeking direct accreditation from FDA in FY2026, you will be required to pay the stated application fee.
Initial and Renewal Recognition Fees
For fiscal year 2026, the FDA announces the initial and renewal fee rates that accreditation bodies must pay when applying to be recognized in the FSMA third-party certification program. If you plan to apply for new recognition or renew recognition as an accreditation body, you will need to pay these application or renewal fees in FY2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20085, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Voluntary Improvement Program
The FDA is asking for public feedback by November 2, 2026, on its Voluntary Improvement Program (VIP), which helps medical device makers improve quality through third-party reviews. This program supports better products and safer devices without adding extra costs or deadlines for companies. It’s all about encouraging excellence and teamwork between the FDA, industry, and partners like the Medical Device Innovation Consortium.
Previous / Next Documents
Previous: 2025-14414, Food Safety Modernization Act Domestic and Foreign Facility Reinspection, Recall, and Importer Reinspection Fee Rates for Fiscal Year 2026
Starting in fiscal year 2026, the FDA is updating fees for checking food facilities again, handling recall slip-ups, and re-inspecting importers. If you run or import food businesses, expect some changes in costs and timing for these inspections. These updates help keep our food safe and make sure everyone plays by the rules.
Next: 2025-14416, Biosimilar User Fee Rates for Fiscal Year 2026
The FDA is setting new fees for companies working on biosimilar drugs in fiscal year 2026. If you’re developing or getting approval for these drugs, expect some updated costs starting October 1, 2025. These fees help the FDA keep reviews speedy and safe, so everyone wins!